Business Context and Reporting Period
This Form 8-K Current Report from Alnylam Pharmaceuticals, Inc. covers events occurring on June 21, 2012, with the report filed on June 27, 2012. The filing details executive compensation adjustments and the results of the 2012 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on corporate governance and executive compensation.
- Shares Outstanding: 51,893,758 shares as of the April 25, 2012 record date.
- Executive Compensation Adjustments:
- Akshay K. Vaishnaw, M.D., Ph.D.: Promoted to Executive Vice President and Chief Medical Officer. Annual base salary increased to $450,000 (from $396,550). Target award percentage under the 2012 Annual Incentive Program increased to 50% (from 40%), with a maximum cash award opportunity of $225,000.
- Barry E. Greene: President and Chief Operating Officer. Annual base salary increased to $500,000 (from $449,904). Maximum cash award opportunity under the 2012 Plan is $250,000.
Material Changes
Material changes reported include the promotion of Dr. Vaishnaw and salary increases for both Dr. Vaishnaw and Mr. Greene to align compensation with industry peer groups. Additionally, the Board re-elected three Class II directors and received stockholder approval for executive compensation and auditor ratification.
Guidance, Outlook, and Voting Results
The filing contains no financial guidance or outlook. It reports the following voting outcomes from the Annual Meeting:
- Director Elections (Class II):
- Dennis A. Ausiello, M.D.: 33,349,268 For; 139,336 Withheld.
- John K. Clarke: 31,704,248 For; 1,784,356 Withheld.
- Marsha H. Fanucci: 32,468,371 For; 1,020,233 Withheld.
- Executive Compensation (Say-on-Pay): Approved with 30,257,308 For; 3,176,758 Against; 54,538 Abstentions.
- Auditor Ratification: PricewaterhouseCoopers LLP ratified with 41,734,654 For; 276,086 Against; 38,057 Abstentions.
Investor Verification Checklist
- Verify the competitive positioning of the new executive compensation packages against the stated industry peer group.
- Review the full proxy statement for details on the directors' qualifications and the specific rationale for the compensation increases.
- Confirm the impact of the 8,560,193 broker non-votes on the quorum and voting thresholds for future proposals.
- Check subsequent filings for any changes in the Company's financial status or clinical trial progress, as this 8-K contains no operational or financial performance data.